- LTS Lohmann has expanded its service portfolio to include CDMO services for ophthalmic drug delivery solutions at its Lakewood, New Jersey facility.
- The offering will initially focus on product development through clinical manufacturing of sterile ophthalmic products in preservative-free multidose devices.
LTS Lohmann Therapie-Systeme AG announced the expansion of its service portfolio to include contract development and manufacturing organization (CDMO) services for ophthalmic drug delivery solutions. The new capabilities will be based at the company’s facility in Lakewood, New Jersey, supporting U.S. and international markets.
The initial offering will focus on product development through clinical manufacturing of sterile ophthalmic products, including those filled in preservative-free multidose devices. The company stated that its existing aseptic manufacturing capabilities in nasal sprays and vials provide a foundation for meeting regulatory and quality requirements in ophthalmic treatments.
LTS plans to extend its CDMO services over time to cover the full product lifecycle, from formulation development to commercial manufacturing. The expansion is intended to address demand for specialized drug delivery solutions in ophthalmology and related therapeutic areas.
“Ophthalmic drug delivery presents unique challenges in terms of sterility, efficacy, and patient safety.”
Bas van Buijtenen, CEO of LTS
The company stated that the new offering is designed to support pharmaceutical and biotechnology companies seeking U.S.-based contract manufacturing partners. The initiative reflects LTS’s broader strategy to expand its technology platforms and service capabilities in drug delivery.
